Rapt Therapeutics Inc

Rapt Therapeutics, Inc. operates as a clinical stage immunology-based biopharmaceutical company. It focuses on discovering, developing and commercializing oral small molecule therapies for patients in oncology and inflammatory diseases.. The company was founded in 2015 and is headquartered in South San Francisco, CA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Rapt Therapeutics, Inc. operates as a clinical stage immunology-based biopharmaceutical company, which engages in the discovery, development, and commercialization of oral small molecule therapies for patients in oncology and inflammatory diseases. The company was founded in 2015 and is headquartered in South San Francisco, CA.

SOUTH SAN FRANCISCO, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced that members of the RAPT management team will participate in the following investor conferences in November:

RAPT Therapeutics to Participate in Several Upcoming Investor Conferences in November

SOUTH SAN FRANCISCO, Calif., Oct. 18, 2023 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced it will present two posters on FLX475, its oncology drug candidate, at the Society for Immunotherapy of Cancer 2023 Annual Meeting taking place November 3-5, 2023 in San Diego, CA.

RAPT Therapeutics Announces Two FLX475 Presentations at the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting

Akero Therapeutics Inc

CymaBay Therapeutics

MoonLake Immunotherapeutics

Olema Pharmaceuticals

Option Care Health

Sensus Healthcare

While the health innovation space presents wild risks, you could potentially swing the odds in your favor with strong buy biotech stocks. Specifically, these ideas represent publicly traded biotechnology firms that enjoy the highest possible consensus rating among Wall Street analysts.

7 ‘Strong Buy' Biotech Stocks to Rejuvenate Your Portfolio

SOUTH SAN FRANCISCO, Calif., Aug. 30, 2023 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced that members of the RAPT management team will participate in the following investor conferences in September:

RAPT Therapeutics to Participate in Several Upcoming Investor Conferences in September

The average of price targets set by Wall Street analysts indicates a potential upside of 90.5% in Rapt Therapeutics (RAPT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

How Much Upside is Left in Rapt Therapeutics (RAPT)? Wall Street Analysts Think 90.48%

SOUTH SAN FRANCISCO, Calif., Aug. 11, 2023 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today reported financial results for the second quarter and the six months ended June 30, 2023.

RAPT Therapeutics Reports Second Quarter 2023 Financial Results

RAPT Therapeutics has solid data from early trials but has a habit of going down on good data. One reason could be that the stock is heavily institution-owned. Their next major catalyst is one year away.

RAPT Therapeutics: Major Catalysts Are A Long Way Off

SOUTH SAN FRANCISCO, Calif., June 07, 2023 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced that Brian Wong, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the Goldman Sachs Global Healthcare Conference on Monday, June 12, 2023 at 1:20 p.m. PT.

RAPT Therapeutics to Participate in the Goldman Sachs Global Healthcare Conference

-FLX475-treated patients exhibited significant changes in immune pathways likely to enhance an antitumor response -FLX475 modifies the tumor microenvironment (TME) to resemble those of responders to anti-PD(L)1 monotherapy -Data to be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting   SOUTH SAN FRANCISCO, Calif., May 25, 2023 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced biomarker data for FLX475 from its ongoing FLX475-02 Phase 1/2 clinical trial which corroborate the clinical activity of FLX475 reported in Epstein-Barr virus-positive (EBV+) lymphoma, EBV+ gastric cancer and non-small cell lung cancer (NSCLC), as well as the mechanism of this novel CCR4 antagonist.

RAPT Therapeutics to Present Biomarker Data Corroborating Demonstrated Clinical Activity and Mechanism of Action of FLX475 in Advanced Cancers

SOUTH SAN FRANCISCO, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today reported financial results for the first quarter ended March 31, 2023.

RAPT Therapeutics Reports First Quarter 2023 Financial Results

SOUTH SAN FRANCISCO, Calif., May 03, 2023 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced the appointment of Michael Listgarten as General Counsel.

RAPT Therapeutics Announces the Appointment of Michael Listgarten as General Counsel

SOUTH SAN FRANCISCO, Calif., April 26, 2023 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced it will present a poster on FLX475, its lead oncology drug candidate, at the 2023 American Society of Clinical Oncology (ASCO) annual meeting taking place June 2-6, 2023 at the McCormick Place Convention Center in Chicago, IL.

RAPT Therapeutics Announces FLX475 Poster Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

NEW YORK , April 3, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of RAPT Therapeutics, Inc. ("RAPT" or the "Company") (NASDAQ: RAPT). Such investors are advised to contact Robert S.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of RAPT Therapeutics, Inc. - RAPT

RAPT Therapeutics, Inc. is a clinical-stage biotech developer of specific small molecules that can modulate the critical immune drivers of inflammatory diseases and oncology. The pipeline of investigational therapies includes FLX475 as a potential treatment for advanced cancers and RPT193, which targets atopic dermatitis and asthma.

RAPT Therapeutics: Potential Strong Upside Ahead

SOUTH SAN FRANCISCO, Calif., March 29, 2023 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced that it has initiated its global 14-week randomized, double-blind, placebo-controlled Phase 2a clinical trial to evaluate the efficacy and safety of RPT193 as an oral, once-daily monotherapy in patients with moderate-to-severe asthma.

RAPT Therapeutics Announces Initiation of Phase 2a Trial of RPT193 in Patients with Moderate-to-Severe Asthma

Company maintains strong cash position of $249.1 million Company maintains strong cash position of $249.1 million

RAPT Therapeutics Reports Fourth Quarter And Year End Financial Results

Rapt Therapeutics (RAPT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Rapt Therapeutics (RAPT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

The average of price targets set by Wall Street analysts indicates a potential upside of 57.6% in Rapt Therapeutics (RAPT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts See a 57.57% Upside in Rapt Therapeutics (RAPT): Can the Stock Really Move This High?

Rapt Therapeutics (RAPT) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

What Makes Rapt Therapeutics (RAPT) a Good Fit for 'Trend Investing'

The mean of analysts' price targets for Rapt Therapeutics (RAPT) points to a 66.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Think Rapt Therapeutics (RAPT) Could Surge 66.77%: Read This Before Placing a Bet

SOUTH SAN FRANCISCO, Calif., Feb. 07, 2023 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced that Brian Wong, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the SVB Securities Global Biopharma Conference on Tuesday, February 14, 2023 at 1:40 p.m. Eastern Time.

RAPT Therapeutics to Participate in the SVB Securities Global Biopharma Conference

Here's Why 'Trend' Investors Would Love Betting on Rapt Therapeutics (RAPT)

SOUTH SAN FRANCISCO, Calif., Jan. 03, 2023 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced that Brian Wong, M.D., Ph.D., President and Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023 at 3:00 p.m. Pacific Time.

RAPT Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

The mean of analysts' price targets for Rapt Therapeutics (RAPT) points to a 122.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Does Rapt Therapeutics (RAPT) Have the Potential to Rally 122% as Wall Street Analysts Expect?

Data Presented at ESMO Immuno-Oncology Congress Data Presented at ESMO Immuno-Oncology Congress

RAPT Therapeutics Presents Update from its Phase 1/2 Clinical Trial for FLX475 as Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Cancer

News for Rapt Therapeutics Inc Stock (RAPT)